Finding Fragile X Biomarkers – From Transcriptomics to Behavior in Patients

November 6, 2018

FRAXA funded a study using blood-based transcriptomics to find reliable Fragile X biomarkers. This unique approach links molecular data to behavior for future trials.

Read More »
Peter Vanderklish

Altered Neural Excitability and Chronic Anxiety in a Mouse Model of Fragile X

September 13, 2017

With a $35,000 grant from FRAXA, Dr. Peter Vanderklish at Scripps Research Institute, and colleagues, explored the basis of anxiety in Fragile X syndrome.

Read More »
Fragile X researchers tackle Anxiety

Fragile X Research Tackles High Anxiety – Peter Vanderklish

February 9, 2017

Peter Vanderklish studies the brain circuits driving severe anxiety in Fragile X, identifying targets in stress pathways to develop treatments that reduce anxiety and improve daily life.

Read More »
Peter Vanderklish, PhD, at Scripps Research Institute, FRAXA research grant

Targeting AMP-Activated Protein Kinase Pathway in Fragile X Syndrome

September 13, 2015

With this grant from FRAXA, Dr. Peter Vanderklish explored AMPK activators to treat Fragile X. Both metformin and resveratrol, found in red wine, are AMPK activators.

Read More »

Categories

FRAXA Funded Research

Current Research Grants (37)